Stock Track | Elanco Animal Health Soars 5.21% in Intraday Trading After Q4 Earnings Beat and Raised 2026 Guidance

Stock Track

Yesterday

Elanco Animal Health Inc's stock surged 5.21% in intraday trading on Tuesday, following the company's release of better-than-expected fourth-quarter results and optimistic guidance for 2026.

The animal health company reported Q4 2025 revenue of $1.144 billion, beating analyst estimates of $1.093 billion and representing 12% year-over-year growth. Adjusted earnings per share came in at $0.13, exceeding the consensus estimate of $0.11. For the full year 2026, Elanco projected revenue between $4.95 billion and $5.02 billion, above the FactSet estimate of $4.93 billion, with adjusted EPS guidance of $1.00 to $1.06 compared to the $1.03 estimate.

Key growth drivers included strong performance from new products like Credelio Quattro and Zenrelia in pet health, with Zenrelia reaching approximately 50% of U.S. clinics. The company also raised its 2026 innovation revenue target to $1.15 billion and highlighted recent USDA approval for Befrena, a new treatment for canine allergic dermatitis. CEO Jeff Simmons credited growth across all business units, supported by price increases and volume growth in most major markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119347439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119347439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119347439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119347439","market":"us","top_or_hot":-1,"title":"Stock Track | Elanco Animal Health Soars 5.21% in Intraday Trading After Q4 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Elanco Animal Health Inc's stock surged 5.21% in intraday trading on Tuesday, following the company's release of better-than-expected fourth-quarter results and optimistic guidance for 2026.</p><p>The animal health company reported Q4 2025 revenue of $1.144 billion, beating analyst estimates of $1.093 billion and representing 12% year-over-year growth. Adjusted earnings per share came in at $0.13, exceeding the consensus estimate of $0.11. For the full year 2026, Elanco projected revenue between $4.95 billion and $5.02 billion, above the FactSet estimate of $4.93 billion, with adjusted EPS guidance of $1.00 to $1.06 compared to the $1.03 estimate.</p><p>Key growth drivers included strong performance from new products like Credelio Quattro and Zenrelia in pet health, with Zenrelia reaching approximately 50% of U.S. clinics. The company also raised its 2026 innovation revenue target to $1.15 billion and highlighted recent USDA approval for Befrena, a new treatment for canine allergic dermatitis. CEO Jeff Simmons credited growth across all business units, supported by price increases and volume growth in most major markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Elanco Animal Health Soars 5.21% in Intraday Trading After Q4 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Elanco Animal Health Soars 5.21% in Intraday Trading After Q4 Earnings Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Elanco Animal Health Inc's stock surged 5.21% in intraday trading on Tuesday, following the company's release of better-than-expected fourth-quarter results and optimistic guidance for 2026.</p><p>The animal health company reported Q4 2025 revenue of $1.144 billion, beating analyst estimates of $1.093 billion and representing 12% year-over-year growth. Adjusted earnings per share came in at $0.13, exceeding the consensus estimate of $0.11. For the full year 2026, Elanco projected revenue between $4.95 billion and $5.02 billion, above the FactSet estimate of $4.93 billion, with adjusted EPS guidance of $1.00 to $1.06 compared to the $1.03 estimate.</p><p>Key growth drivers included strong performance from new products like Credelio Quattro and Zenrelia in pet health, with Zenrelia reaching approximately 50% of U.S. clinics. The company also raised its 2026 innovation revenue target to $1.15 billion and highlighted recent USDA approval for Befrena, a new treatment for canine allergic dermatitis. CEO Jeff Simmons credited growth across all business units, supported by price increases and volume growth in most major markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAN","symbol_name":"Elanco Animal Health Inc","start_time":0,"source_url":"","article_id":"1119347439","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119347439","pubTimestamp":1771944591,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Elanco Animal Health Inc's stock surged 5.21% in intraday trading on Tuesday, following the company's release of better-than-expected fourth-quarter results and optimistic guidance for 2026.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELAN":"Elanco Animal Health Inc"},"translate_title":"个股追踪|Elanco Animal Health第四季度盈利超预期并上调2026年指引后盘中飙升5.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":1},"content_text":"Elanco Animal Health Inc's stock surged 5.21% in intraday trading on Tuesday, following the company's release of better-than-expected fourth-quarter results and optimistic guidance for 2026.The animal health company reported Q4 2025 revenue of $1.144 billion, beating analyst estimates of $1.093 billion and representing 12% year-over-year growth. Adjusted earnings per share came in at $0.13, exceeding the consensus estimate of $0.11. For the full year 2026, Elanco projected revenue between $4.95 billion and $5.02 billion, above the FactSet estimate of $4.93 billion, with adjusted EPS guidance of $1.00 to $1.06 compared to the $1.03 estimate.Key growth drivers included strong performance from new products like Credelio Quattro and Zenrelia in pet health, with Zenrelia reaching approximately 50% of U.S. clinics. The company also raised its 2026 innovation revenue target to $1.15 billion and highlighted recent USDA approval for Befrena, a new treatment for canine allergic dermatitis. CEO Jeff Simmons credited growth across all business units, supported by price increases and volume growth in most major markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}